SCHEMBL22636741

SCHEMBL22636741

Nc1cc(-c2cn[nH]c2)ccc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 3/20 0.59
AKT1 P31749 1/20 0.59
ROCK2 O75116 3/20 0.47
ROCK1 Q13464 1/20 0.47
FEN1 P39748 2/20 0.47
CLK2 P49760 2/20 0.46
HIPK1 Q86Z02 2/20 0.46
HIPK2 Q9H2X6 2/20 0.46
HIPK3 Q9H422 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46
CLK1 P49759 1/20 0.46
DYRK2 Q92630 1/20 0.45
CHEK1 O14757 2/20 0.43
PIM1 P11309 1/20 0.43
LMNA P02545 1/20 0.42
ALK Q9UM73 1/20 0.42
LRRK2 Q5S007 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BTK Q06187 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430626 1.00 AKT2 (0.59) AKT2AKT1ROCK2ROCK1FEN1
SCHEMBL29430739 0.85 MAPK1 (0.51) AKT2AKT1ROCK2ROCK1FEN1
SCHEMBL22636821 0.85 MAPK1 (0.51) AKT2AKT1ROCK2ROCK1FEN1
SCHEMBL22637441 0.84 FEN1 (0.51) AKT2AKT1ROCK2FEN1CLK2
SCHEMBL29430842 0.84 FEN1 (0.51) AKT2AKT1ROCK2FEN1CLK2
SCHEMBL29430735 0.82 FEN1 (0.46) AKT2AKT1ROCK2ROCK1FEN1
SCHEMBL22636660 0.82 FEN1 (0.46) AKT2AKT1ROCK2ROCK1FEN1
SCHEMBL31482437 0.80 AKT2 (0.63) AKT2AKT1ROCK2ROCK1FEN1
SCHEMBL16872766 0.78 AKT2 (0.95) AKT2AKT1ROCK2CLK2HIPK1
SCHEMBL4412044 0.78 HSD17B10 (0.59) LMNAALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 AKT2 2545/4885AKT1 2403/4885ROCK2 4597/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 AKT2 2331/4885AKT1 2175/4885ROCK2 4591/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 AKT2 2308/4885AKT1 2180/4885ROCK2 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.